Concomitant quantification of targeted drug delivery and biological response in individual cells.
Targeted therapies result in heterogeneous drug delivery, often with highly variable drug uptake in the targeted cells and significant numbers of cells that are essentially untargeted. However both the variably targeted cells and neighboring bystander cells may respond to the treatment. Using ionizing radiation as an example of a targeted therapeutic agent, we describe a quantitative immunofluorescence-based approach for concomitant quantification of exposure and measurement of biological responses in both targeted and bystander cells. Cultures of human skin fibroblasts are co-pulse-labeled with 3H-deoxycytidine (3H-dC) and bromodeoxyuridine (BrdU). The labeled cells, identified by BrdU immunofluorescence, are internally irradiated by low-energy beta-particles emitted by incorporated 3H-dC. BrdU immunofluorescence intensity is proportional to radioactivity incorporated and, therefore, to radiation dose rate. Cell-cycle arrest in G2 is measured in labeled cells as function of dose rate. Stress responses in bystander cells, indicated by a G1 checkpoint, are concomitantly measured with a flow cytometric-cumulative labeling index (FCM-CLI) assay. The overall approach presented herein may be useful in the context of evaluating responses to targeted drug delivery.
Pinto
Massimo
M
University of Medicine and Dentistry of New Jersey, Newark, NJ 07101, USA.
Howell
Roger W
RW
D000918:Antibody Specificity / Q000528:radiation effects; D001973:Bromodeoxyuridine / Q000378:metabolism; D024201:Bystander Effect / Q000528:radiation effects; D002478:Cells, Cultured; D004247:DNA / Q000096:biosynthesis / Q000378:metabolism; D004261:DNA Replication / Q000528:radiation effects; D016503:Drug Delivery Systems; D005347:Fibroblasts / Q000166:cytology* / Q000528:radiation effects; D005434:Flow Cytometry; D016195:G2 Phase / Q000528:radiation effects; D006801:Humans; D007065:Idoxuridine / Q000378:metabolism; D011839:Radiation, Ionizing; D011874:Radiometry; D015203:Reproducibility of Results; D013194:Staining and Labeling
D004247:DNA; D001973:Bromodeoxyuridine; D007065:Idoxuridine
Nat Methods. 2005 Mar;2(3):167-9
15782184
Radiother Oncol. 1994 Apr;31(1):1-13
8041894
J Nucl Med. 2006 Jun;47(6):1049-58
16741316
Pathol Oncol Res. 2006;12(2):118-24
16799716
Radiat Prot Dosimetry. 2006;122(1-4):252-5
17185313
Nat Methods. 2006 Aug;3(8):581
16892523
Radiat Res. 2001 Feb;155(2):288-96
11175663
Cancer Res. 2001 Apr 1;61(7):3039-44
11306485
Micron. 2002;33(2):127-32
11567881
Cytometry. 2001 Oct 15;46(5):296-306
11746105
Curr Gene Ther. 2002 Sep;2(3):307-22
12189718
Cytometry A. 2003 Jul;54(1):1-7
12820115
Int J Pharm. 2003 Aug 27;262(1-2):1-11
12927382
Curr Cancer Drug Targets. 2004 Feb;4(1):53-64
14965267
J Immunol Methods. 1986 Oct 23;93(1):97-101
3772110
Cytometry. 1987 Jul;8(4):372-6
3113895
Radiat Res. 1993 Mar;133(3):289-96
8451379
Radiat Res. 1999 Jul;152(1):88-97
10428683
Cancer Res. 1998 May 1;58(9):2036-41
9581850
Mutat Res. 2006 May 11;597(1-2):119-32
16438994